Targeting Endoplasmic Reticulum Stress in Human Hypertension
ConditionHypertension
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of North Texas Health Science Center
About this trial
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
Eligibility criteria
Qualifiers
18 to 80 years of age
No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
Systolic blood pressure <140 mmHg; diastolic blood pressure <90 mmHg (obtained at the Screening and Familiarization Visit)
Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)
Disqualifiers
Not meeting the defined age criteria
Body mass index (BMI) >35 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
Positive pregnancy test
Trial design
Treatments tested in this trial
- TUDCA
- Placebo
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov